Kyle R A, Gailani S, Seligman B R, Blom J, McIntyre O R, Pajak T F, Holland J F
Cancer Treat Rep. 1979 Aug;63(8):1265-9.
Eighty-nine patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide plus prednisone (CP) (47 patients) or cyclophosphamide plus BCNU plus prednisone (CBP) (42 patients). No differences were detected in the two groups prior to therapy. Objective responses occurred in three (7%) of the CP patients and in seven (17%) of the CBP patients. About 40% of the patients in each group achieved some response. Toxic reactions consisted mainly of leukopenia and thrombocytopenia. Median survival was not different in the two groups. The median survival time was 31 months among those patients with an objective response and 9.4 months among those without an objective response. The addition of BCNU to CP increased the frequency of objective response, but not significantly. This triple combination (CBP) cannot be recommended.
89例对美法仑耐药的多发性骨髓瘤患者被随机分为两组，分别接受环磷酰胺加泼尼松（CP）治疗（47例患者）或环磷酰胺加卡氮芥加泼尼松（CBP）治疗（42例患者）。治疗前两组未检测到差异。CP组有3例（7%）患者出现客观缓解，CBP组有7例（17%）患者出现客观缓解。每组约40%的患者有一定反应。毒性反应主要包括白细胞减少和血小板减少。两组的中位生存期无差异。有客观反应的患者中位生存时间为31个月，无客观反应的患者中位生存时间为9.4个月。在CP方案中加入卡氮芥可增加客观缓解的频率，但无显著差异。不推荐这种三联方案（CBP）。
